GAITHERSBURG, Md., Dec. 6 /PRNewswire-FirstCall/ -- MedImmune, Inc. announced today that it continues to build strength and depth in its management ranks through promotions and new hires. Recognizing their leadership and outstanding performance, MedImmune has promoted William C. Bertrand, Jr., J.D. to senior vice president, general counsel, secretary and corporate compliance officer; Pamela J. Lupien to senior vice president, human resources; Genevieve Losonsky, M.D. to vice president, clinical development, infectious disease; and Robert Walker, M.D. to vice president, clinical development, inflammatory disease. In addition, MedImmune has recruited Anthony Luttrell as vice president, quality; Frank J. Malinoski, M.D., Ph.D. as vice president, medical affairs, infectious disease; and John J. Whalen, M.D. as vice president, clinical development operations.
“Bill Bertrand, Pam Lupien, Genny Losonsky and Bob Walker have led by example and delivered results. They exemplify our core values of high integrity, entrepreneurial spirit, teamwork and strong work ethic,” said David M. Mott, chief executive officer and president. “We are grateful for the opportunity to recognize their contributions to our success through these promotions and look forward to their leadership in their new roles at MedImmune.”
Mott added: “As MedImmune continues to grow, it is critical that we selectively complement the growth of our existing leadership team with the addition of outside talent. Our ability to attract extraordinarily talented executives to the team has never been greater, as exemplified by the addition of Tony Luttrell, Frank Malinoski and Jack Whalen. We welcome them and look forward to their contributions to MedImmune’s continued growth.”
Executive Promotions
William C. Bertrand, Jr., J.D. has been promoted to senior vice president, general counsel, secretary and corporate compliance officer. Mr. Bertrand joined MedImmune in 2001, and held positions of increasing responsibility prior to his promotion. Under his leadership, MedImmune’s legal affairs department has grown significantly and has steadily increased its ability to lead and manage a broad range of corporate legal matters, intellectual property issues and litigation. Mr. Bertrand and his team are sought out as strategic partners by our internal business leaders. Prior to joining MedImmune, he served in various legal positions at Pharmacia Corporation, including litigation counsel, senior corporate counsel and associate general counsel. Mr. Bertrand spent the earlier part of his legal career as an associate general counsel for a life insurance company, and a partner at Dickinson, Wright, Moon, Van Dusen & Freeman. Mr. Bertrand holds a bachelor of science degree in biology from Wayne State University and a juris doctorate (cum laude) from University of Wisconsin - Madison. Mr. Bertrand was recently named “Top Washington Lawyer - General Counsel” by the Washington Business Journal.
Pamela J. Lupien has been promoted to senior vice president, human resources. Ms. Lupien joined MedImmune as vice president of human resources in April 2002. She spearheaded the recent growth in MedImmune’s human resources organization, which includes the environmental health and safety function in six locations and three countries. Her organization has recently completed the implementation of a restructured compensation model, new leadership development program and a corporate capabilities program, which aims to systematically enable the development of MedImmune’s employees, and accelerate the growth of leadership talent within the organization. Prior to joining MedImmune, Ms. Lupien worked for the Orbital Sciences Corporation as senior vice president, human resources, from 2000 until 2002. Previously, she held a variety of increasingly responsible positions at James Martin & Company, Betzdearborn, Inc., Freuhauf Trailer Corporation, and IBM Corporation. Ms. Lupien has a bachelor’s degree in social sciences from the University of South Florida and a master’s degree in business administration from Jacksonville University.
Genevieve Losonsky, M.D. has been promoted to vice president, clinical development, infectious disease. Since joining the company in 2002, Dr. Losonsky has served as project director for several clinical programs involving MedImmune’s respiratory syncytial virus prevention franchise, including the Numax(TM) (motavizumab) program. Prior to joining MedImmune, Dr. Losonsky held faculty positions at the University of Maryland School of Medicine, where she was an associate professor in the Department of Pediatrics and Medicine, and at the Center for Vaccine Development, where she served as chief of the Applied Immunology Laboratory. Dr. Losonsky has published approximately 110 journal articles and 50 abstracts related to infectious diseases and vaccines, in addition to multiple book chapters and symposia. She received a bachelor’s degree in biology and psychology from New York University and a medical degree from the State University of New York at Buffalo. Dr. Losonsky completed her residency in pediatrics at Yale New Haven Hospital, Yale University Department of Pediatrics, and also completed a research and clinical fellowship in infectious diseases at Buffalo Children’s Hospital and a National Institutes of Health (NIH) fellowship in infectious diseases at Johns Hopkins University. She currently is a peer reviewer for the pediatric journals Pediatric Infectious Diseases, Infection and Immunity, and Pediatrics, and a member of the Society for Pediatric Research and the Infectious Disease Society of America.
Robert Walker, M.D., has been promoted to vice president, clinical development, inflammatory disease. In this position, he will oversee MedImmune’s clinical trials of new product candidates aimed at preventing or treating various autoimmune and pulmonary diseases. Dr. Walker is currently the project director for the intranasal influenza vaccine program at MedImmune and will continue to be the senior project lead for that program. Prior to joining the biotechnology industry, Dr. Walker was a senior investigator in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases and a senior attending physician in Critical Care Medicine at the NIH Clinical Center. During this time, Dr. Walker did research in human immunodeficiency virus (HIV) and immunology. Dr. Walker holds a bachelor of arts degree from Vassar College and a medical degree from the University of Maryland School of Medicine. He completed an internal medicine residency at George Washington University and a fellowship in pulmonary and critical care medicine at the University of Pennsylvania.
New Executives at MedImmune
Anthony Luttrell has been appointed MedImmune’s vice president, quality. In this position, Mr. Luttrell is responsible for the strategic direction of MedImmune’s quality organization and oversees the company’s quality assurance, quality control, compliance, validation and clinical quality departments. Mr. Luttrell began consulting with MedImmune in 2000. Previously, he held quality- related management positions at Parke-Davis/Warner-Lambert, Baxter Healthcare, Kendall McGaw Pharmaceuticals, Solvay Animal Health, Inc. and BioPort Corporation. Mr. Luttrell brings to MedImmune more than 25 years of experience in the pharmaceutical, biopharmaceutical and medical device industries. He holds a bachelor’s degree in biology from Spring Arbor College in Michigan, an MBA from Oakland University in Michigan, and a certification from the Minnesota Executive Development Program of the Carlson School of Business at the University of Minnesota.
Frank J. Malinoski, M.D., Ph.D. joins MedImmune as vice president, medical affairs, infectious disease, where he will oversee medical programs relating to marketed infectious disease products, including clinical trials and medical information. Prior to joining MedImmune, Dr. Malinoski served as president of his consulting practice, TD Consultancy. He also worked for pharmaceutical and biotechnology companies such as Oxxon Therapeutics, Inc. and Wyeth, where he held positions as chief medical officer and executive vice president, development, and vice president, global business development, respectively. Previously, Dr. Malinoski served as a private practice physician in Frederick, Maryland. Dr. Malinoski received a bachelor’s degree in biology from Colby College in Waterville, Maine, a Ph.D. in microbiology from Rutgers University and a medical degree from Albany Medical College.
John J. Whalen, M.D., has joined MedImmune as vice president, clinical development operations. In this role, Dr. Whalen provides leadership, strategic planning and effective management to all functional areas within clinical operations, data management, biostatistics and programming groups. Prior to joining MedImmune, Dr. Whalen worked for the clinical contract research organization, Scirex Corporation, as general manager, clinical development services. Dr. Whalen has more than 25 years of experience in the pharmaceutical, contract research and biotechnology industries. Prior to Scirex, he held positions in clinical research and operations at Merck, Sharp and Dohme Research Laboratories, G.H. Besselaar Associates (now Covance), Alpha Therapeutic Corporation and Transcend Therapeutics, Inc. He holds a bachelor of science degree in physics from Rensselaer Polytechnic Institute, a medical degree from the University of Virginia Medical School, and completed an internal medicine residency training at Memorial Sloan Kettering Cancer Center and North Shore University Hospital.
About MedImmune
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.
MedImmune, Inc.
CONTACT: Media: Clarencia Stephen, +1-301-398-4073 or Jamie Lacey,+1-301-398-4035, Investors: Peter Vozzo, +1-301-398-4358 or John Filler,+1-301-398-4086, all of MedImmune, Inc.
Web site: http://www.medimmune.com//
